Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI
Executive Summary
The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.
You may also be interested in...
BMS’s Plans For Zeposia In Crohn’s Dubious Following Phase III Miss
The oral S1P modulator, approved to treat ulcerative colitis and MS, missed its primary endpoint in the first of two Phase III induction studies in moderate-to-severe Crohn’s disease.
Bausch’s Amiselimod Hits Phase II Target, But More Clarity Needed
The company reported positive topline data for the drug in ulcerative colitis, but analysts noted caveats about its earliness as well as lackluster performance to date by others in the S1P class.
Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.